Interpatient and intrapatient variability in organ absorbed doses during [177Lu]Lu-DOTATATE therapy for neuroendocrine tumors.
BACKGROUND Peptide receptor radionuclide therapy (PRRT) with lutetium-177 labeled somatostatin analogues is an established treatment for patients with advanced neuroendocrine tumors (NETs). There is growing evidence of a dose-response relationship. Considering critical organ exposure, most patients are treated with fix...